Evidence map›Paper›PMID 39680465›Full record

ArticleThe Journal of clinical investigation2024

Crizanlizumab for retinal vasculopathy with cerebral leukoencephalopathy in a phase II clinical study.

Wilson X Wang, Dan Spiegelman, P Kumar Rao, Rennie L Rhee, Andria L Ford, Jonathan J Miner, Rajendra S Apte

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical investigation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Microglial polarization in retinal neovascularization: Friend or foe?Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Wilson X WangJohn F. Hardesty, MD Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri, USA.
Dan SpiegelmanJohn F. Hardesty, MD Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri, USA.
P Kumar RaoJohn F. Hardesty, MD Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri, USA.
Rennie L RheeDepartment of Medicine and RVCL Research Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Andria L FordDepartment of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.
Jonathan J MinerDepartments of Medicine and Microbiology, Colton Center for Autoimmunity, and RVCL Research Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Rajendra S ApteJohn F. Hardesty, MD Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri, USA.

Funding

Role of TREX1 in age-related hereditary leukoencephalopathyR01NS131480 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI Jonathan J Miner · 2023 to 2026
$3.2M
NINDS NIH HHS R01 NS131480
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39680465
PMCPMC11645139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.